Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
<p>Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.</p>
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | , , , , , , , , , , , , , , , , , , , , , |
| 出版: |
2025
|
| 主題: | |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| _version_ | 1851480969401335808 |
|---|---|
| author | Robert W. Lentz (17013559) |
| author2 | Julie Lang (20519739) Todd M. Pitts (17013577) Patrick Blatchford (22652193) Junxiao Hu (16157686) Kimberly R. Jordan (15049505) Adrie Van Bokhoven (22652196) Stacey M. Bagby (17013565) Adrian T.A. Dominguez (19529151) Cameron A. Binns (22652199) Hannah R. Robinson (19529136) Nicole Balmaceda (22652202) Emily Baiyee (22652205) Alexis D. Leal (17013562) Sunnie S. Kim (19529139) S. Lindsey Davis (14032353) Christopher H. Lieu (15018279) Raymond C. Wadlow (22652208) Kristen Spencer (22652211) Aaron J. Scott (15133937) Patrick M. Boland (15037142) Howard S. Hochster (15022088) Wells A. Messersmith (17013568) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Robert W. Lentz (17013559) Julie Lang (20519739) Todd M. Pitts (17013577) Patrick Blatchford (22652193) Junxiao Hu (16157686) Kimberly R. Jordan (15049505) Adrie Van Bokhoven (22652196) Stacey M. Bagby (17013565) Adrian T.A. Dominguez (19529151) Cameron A. Binns (22652199) Hannah R. Robinson (19529136) Nicole Balmaceda (22652202) Emily Baiyee (22652205) Alexis D. Leal (17013562) Sunnie S. Kim (19529139) S. Lindsey Davis (14032353) Christopher H. Lieu (15018279) Raymond C. Wadlow (22652208) Kristen Spencer (22652211) Aaron J. Scott (15133937) Patrick M. Boland (15037142) Howard S. Hochster (15022088) Wells A. Messersmith (17013568) |
| author_role | author |
| dc.creator.none.fl_str_mv | Robert W. Lentz (17013559) Julie Lang (20519739) Todd M. Pitts (17013577) Patrick Blatchford (22652193) Junxiao Hu (16157686) Kimberly R. Jordan (15049505) Adrie Van Bokhoven (22652196) Stacey M. Bagby (17013565) Adrian T.A. Dominguez (19529151) Cameron A. Binns (22652199) Hannah R. Robinson (19529136) Nicole Balmaceda (22652202) Emily Baiyee (22652205) Alexis D. Leal (17013562) Sunnie S. Kim (19529139) S. Lindsey Davis (14032353) Christopher H. Lieu (15018279) Raymond C. Wadlow (22652208) Kristen Spencer (22652211) Aaron J. Scott (15133937) Patrick M. Boland (15037142) Howard S. Hochster (15022088) Wells A. Messersmith (17013568) |
| dc.date.none.fl_str_mv | 2025-11-20T07:20:05Z |
| dc.identifier.none.fl_str_mv | 10.1158/2767-9764.30664320 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_2_from_Phase_II_Clinical_Trial_and_Preclinical_Evaluation_of_a_Novel_CD47_Blockade_Combination_in_Refractory_Microsatellite-Stable_Metastatic_Colorectal_Cancer/30664320 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Checkpoint Blockade Colorectal Cancer Combination Immunotherapy Gastrointestinal Cancers Immunotherapy |
| dc.title.none.fl_str_mv | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_fbe46df41faabcf8fbada73bb89e44ab |
| identifier_str_mv | 10.1158/2767-9764.30664320 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30664320 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W. Lentz (17013559)Julie Lang (20519739)Todd M. Pitts (17013577)Patrick Blatchford (22652193)Junxiao Hu (16157686)Kimberly R. Jordan (15049505)Adrie Van Bokhoven (22652196)Stacey M. Bagby (17013565)Adrian T.A. Dominguez (19529151)Cameron A. Binns (22652199)Hannah R. Robinson (19529136)Nicole Balmaceda (22652202)Emily Baiyee (22652205)Alexis D. Leal (17013562)Sunnie S. Kim (19529139)S. Lindsey Davis (14032353)Christopher H. Lieu (15018279)Raymond C. Wadlow (22652208)Kristen Spencer (22652211)Aaron J. Scott (15133937)Patrick M. Boland (15037142)Howard S. Hochster (15022088)Wells A. Messersmith (17013568)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsCheckpoint BlockadeColorectal CancerCombination ImmunotherapyGastrointestinal CancersImmunotherapy<p>Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.</p>2025-11-20T07:20:05ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/2767-9764.30664320https://figshare.com/articles/dataset/Table_2_from_Phase_II_Clinical_Trial_and_Preclinical_Evaluation_of_a_Novel_CD47_Blockade_Combination_in_Refractory_Microsatellite-Stable_Metastatic_Colorectal_Cancer/30664320CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/306643202025-11-20T07:20:05Z |
| spellingShingle | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer Robert W. Lentz (17013559) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Checkpoint Blockade Colorectal Cancer Combination Immunotherapy Gastrointestinal Cancers Immunotherapy |
| status_str | publishedVersion |
| title | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| title_full | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| title_fullStr | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| title_full_unstemmed | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| title_short | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| title_sort | Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Checkpoint Blockade Colorectal Cancer Combination Immunotherapy Gastrointestinal Cancers Immunotherapy |